12 Results for "

DBCO-PEG3-VC

" in MedChemExpress (MCE) Product Catalog:
Products (12)

12 Results for "DBCO-PEG3-VC" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-111012
CAS No.: 2754384-60-4
Purity:  99.60%
Research Areas:  

Cancer

DBCO-(PEG)3-VC-PAB-MMAE is a agent-linker conjugate for ADC. DBCO-(PEG)3-VC-PAB-MMAE is made by Monomethyl auristatin E (HY-15162) conjugats to DBCO-(PEG)3-vc-PAB linker. DBCO-(PEG)3-VC-PAB-MMAE can be used for the research of cancer . DBCO-(PEG)3-VC-PAB-MMAE is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
loading...
    loading...
Cat. No.: HY-164792
CAS No.: 2754384-70-6
Research Areas:  

Cancer

DBCO-PEG3-VC-Exatecan (compound 25) is a Drug-Linker Conjugate for ADC. DBCO-PEG3-VC-Exatecan contains the ADC linker (DBCO-PEG3-VC) and a DNA topoisomerase I inhibitor Exatecan (HY-13631) .
loading...
    loading...
Cat. No.: HY-P5112A
Synonyms: Azido-PEG3-FLAG TFA
Research Areas:  

Others

Azido-PEG3-DYKDDDDK (azide-PEG3-FLAG) TFA is a multifunctional fusion tag for the purification of recombinant proteins. Azido-PEG3-DYKDDDDK TFA is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups .
loading...
    loading...
Cat. No.: HY-P5112
CAS No.: 2243206-95-1
Synonyms: Azido-PEG3-FLAG
Research Areas:  

Others

Azido-PEG3-DYKDDDDK (azide-PEG3-FLAG) is a multifunctional fusion tag for the purification of recombinant proteins. Azido-PEG3-DYKDDDDK is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups .
loading...
    loading...
Cat. No.: HY-169089
Target:  

Drug Derivative

Research Areas:  

Cancer

RP-182-PEG3-K palmitic acid-NH2 (Compound 1a) is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K palmitic acid-NH2 inhibits CD206 high M2-like macrophage (IC50 of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K palmitic acid-NH2 exhibits antitumor efficacy in mouse B16 melanoma allografts .
loading...
    loading...
Cat. No.: HY-P11270
CAS No.: 2843676-09-3
Synonyms: BGM0504; BG128
Research Areas:  

Metabolic Disease

Relsipatide (BG128) is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Enicepatide can be studied in antidiabetic research .
loading...
    loading...
Cat. No.: HY-P11428
CAS No.: 2425606-55-7
Research Areas:  

Others

DBCO-cyclo (RGDfK) is a clickable DBCO-modified cyclic RGD peptide, and also a DBCO derivative of cyclo (RGDfK) (HY-P0023). DBCO-cyclo (RGDfK) is synthesized via an amide coupling reaction between DBCO-NHS ester and cyclo (RGDfK). DBCO-cyclo (RGDfK) can react with azide groups through copper-free click chemistry (SPAAC) to immobilize RGD peptides onto biomaterials or hydrogels. The RGD sequence in DBCO-cyclo (RGDfK) is recognizable by cellular integrins and promotes cell adhesion. DBCO-cyclo (RGDfK) can be used in studies related to tissue engineering, 3D cell culture, and surface functionalization of biomaterials .
loading...
    loading...
Cat. No.: HY-169089A
Target:  

Drug Derivative

Research Areas:  

Cancer

RP-182-PEG3-K(palmitic acid)-NH2 (Compound 1a) TFA is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K(palmitic acid)-NH2 TFA inhibits CD206 high M2-like macrophage (IC50 of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K(palmitic acid)-NH2 TFA exhibits antitumor efficacy in mouse B16 melanoma allografts .
loading...
    loading...
Cat. No.: HY-P10319
Target:  

PKA

Research Areas:  

Cardiovascular Disease Cancer

RI-STAD-2 is a high-affinity interfering peptide that regulates the subunit RI of protein kinase A (PKA). RI-STAD-2 interferes with the binding of AKAPs and PKA-RI by simulating the interaction between AKAPs' α-helix domain and PKA-RI's dimerization/anchoration (D/D) domain, thereby affecting PKA activity and intracellular localization. RI-STAD-2 can be used to study the role of AKAPs interaction with PKA-RI in pathological processes such as cardiovascular disease and cancer .
loading...
    loading...
loading...
    loading...
Cat. No.: HY-P11488
JR11-PEG3-DOTA-PSMA-03 (Compound 2) is an RDC-related compound containing the chelating agent DOTA (HY-W053583), the JR11 peptide (SSTR2 antagonist), and the PSMA ligand. JR11-PEG3-DOTA-PSMA-03 shows SSTR2-binding affinities and PSMA-binding affinities, with IC50 s of 94.0 nM, 81.8 nM, respectively. JR11-PEG3-DOTA-PSMA-03 can be radiolabeled with [ 68Ga]. [ 68Ga] radiolabeled JR11-PEG3-DOTA-PSMA-03 can be used in diagnostic studies of neuroendocrine differentiated prostate cancer .
loading...
    loading...
Cat. No.: HY-P11485
JR11-PEG3-HBED-CC-PSMA-03 (Compound 1) is an RDC-related compound containing the chelating agent HBED-CC, the JR11 peptide (SSTR2 antagonist), and the PSMA ligand. JR11-PEG3-HBED-CC-PSMA-03 shows SSTR2-binding affinities and PSMA-binding affinities, with IC50 s of 59.2 nM, 57.0 nM, respectively. JR11-PEG3-HBED-CC-PSMA-03 can be radiolabeled with [ 68Ga]. [ 68Ga] radiolabeled JR11-PEG3-HBED-CC-PSMA-03 can be used in diagnostic studies of neuroendocrine differentiated prostate cancer .
loading...
    loading...
  • 1